| Autor: |
B, Zaborska, J, Kłoś, M, Sikora-Frac, B, Cybulska, L, Ceremuzyński |
| Rok vydání: |
2001 |
| Předmět: |
|
| Zdroj: |
Polskie Archiwum Medycyny Wewnetrznej. 104(1) |
| Popis: |
Elevated serum level of triglycerides is a classic indication for fibrates. Micronized fenofibrate is hypolipemic drug with proven safety and efficacy in a view of triglycerides reduction, but according to few papers published so far on the subject is also effective in decreasing elevated total and LDL cholesterol. The aim of study was to confirm results obtained from these few previous studies. Forty seven persons with lipid disturbances (25 males and 22 females, age range 34-71 yrs. mean 48.0) entered the study. Thirty two patients had a history myocardial infarction and fifteen persons without clinical symptoms of heart diseases. All of them were treated with micronized fenofibrate 200 mg daily. Micronized fenofibrate decreased serum concentration of total cholesterol by 13.4% (p0.01), LDL cholesterol by 21.2% (p0.001) and triglycerides by 39.5% (p0.001) in whole group of patients. Most beneficial effects were obtained in persons with mixed hyperlipidemia: reduction of total cholesterol, triglycerides and LDL cholesterol serum levels was 22.4% (p0.01), 52.5% (p0.0001), 25.4% (p0.01), respectively. In individuals with hypercholesterolemia a reduction of total cholesterol by 11% (p0.05) and LDL cholesterol by 15.4% (p0.05) was observed. In the group with hypertriglyceridemia or mixed hyperlipidemia reduction of serum triglycerides concentration by 33.5% (p0.05) was achieved. No significant change in serum HDL cholesterol level in any group was observed. The treatment with micronized fenofibrate was well tolerated. Our study shows that this drug is safe and seems to be effective in some cases with increased serum total and LDL cholesterol level as well. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
